1 / 11

Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer

Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer. Daniel G. Haller, MD University of Pennsylvania Cancer Center. Discussion topics. What is the goal of administering combination vs sequential therapy? What is the evidence for combination versus sequential therapy?

margaret-greene
Download Presentation

Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer Daniel G. Haller, MD University of Pennsylvania Cancer Center

  2. Discussion topics • What is the goal of administering combination vs sequential therapy? • What is the evidence for combination versus sequential therapy? • What are the interim endpoints in studies of sequential therapy? • How are new therapies incorporated into combination or sequential therapy?

  3. Chemotherapy for Metastatic Colorectal Cancer What is the Goal of Combination vs Sequential Therapy? • Overall survival • The gold standard for regulatory approval • Progression-free survival • Surrogate of activity for clinical trials • Marker of clinical benefit • Response rate • Measures of quality of life • Time to symptom worsening

  4. Chemotherapy for Metastatic Colorectal Cancer Combination Chemotherapy (FU/LV With CPT-11 or Oxaliplatin) • RR: range from 34–51% • PFS: range from 6.7–9.3 m • OS: range from 14.8–19.4 m • Statistical superiority for FU/LV/CPT-11 compared to first-line FU/LV • Incremental benefit achieved without marked increase in toxicity or negative impact on QOL • Effects of crossover and surgical therapy

  5. Chemotherapy for Metastatic Colorectal Cancer “There are only two tragedies in life: one is not getting what one wants, and the other is getting it.” Oscar Wilde

  6. Chemotherapy for Metastatic Colorectal Cancer NCCTG Trial N9741 • FU/LV/CPT-11(Saltz) weekly • •FU/LV(de Gramont) + oxaliplatin Q2W • Oxaliplatin + CPT-11Q3W • -Primary endpoint: Survival • -No fixed crossover; no oxaliplatin available • after progression on Saltz regimen R

  7. Chemotherapy for Metastatic Colorectal Cancer FRE-C97-3: FOLFIRI vs FOLFOX • 113 patients/arm • Primary endpoint: PFS • No prior CT, >6mos from adjuvant • Rx, no prior CPT-11 or oxaliplatin Oxaliplatin + de Gramont FU/LV R CPT-11 + de Gramont FU/LV Proc ASCO, abstract 949, 2000

  8. Duration of Chemotherapy MRC-CR06 Trial CIFU De Gramont FU/LV Tomudex R Patients are treated for 12 weeks; if stable or responding, a second randomization to 12 more weeks of therapy or discontinuation

  9. Sequence of Chemotherapy FOCUS Trial Modified de Gramont FU/LV CPT-11 Modified de Gramont FU/LV FU/LV+CPT-11 FU/LV/CPT-11 Modified de Gramont FU/LV FU/LV+oxaliplatin FU/LV/oxaliplatin R • 2100 patients endpoints: PFS, OS, QOL

  10. Chemotherapy for Metastatic Colorectal Cancer Pivotal Trial of Oxaliplatin: EFC 4584 • Response rate in FU/LV and CPT-11 failures • Survival advantage in patients who have failed FU/LV/irinotecan infusional FU/LV(de Gramont) R oxaliplatin infusional FU/LV+oxaliplatin

  11. Chemotherapy for Metastatic Colorectal Cancer Oxaliplatin Trials in US • EFC 4584: in FU/LV/CPT-11 (Saltz) failures • EFC 4585: CPT-11 alone vs CPT-11 + oxaliplatin in FU/LV failures • EFC 4759: oxaliplatin in third-line therapy • EFC 4760: de Gramont FU/LV + oxaliplatin in third-line therapy

More Related